Background Azithromycin is an orally active synthetic macrolide antibiotic with a wide range of anti-bacterial, anti-inflammatory and antiviral properties. It is a safe, inexpensive, generic licenced drug available worldwide and manufactured to scale and is a potential candidate therapy for pandemic coronavirus disease 2019 (COVID-19). Azithromycin was widely used to treat severe SARS-CoV and MERS-CoV, but to date, no randomised data are available in any coronavirus infections. Other ongoing trials are exploring short courses of azithromycin either in early disease, within the first 7 days of symptoms, when azithromycin’s antiviral properties may be important, or late in disease when anti-bacterial properties may reduce the risk of secondary bacterial infection. However, the molecule’s anti-inflammatory properties, including suppression of pulmonary macrophage-derived pro-inflammatory cytokines such as interleukins-1β, -6, -8, and -18 and cytokines G-CSF and GM-CSF may provide a distinct therapeutic benefit if given in as a prolonged course during the period of progression from moderate to severe disease. Methods ATOMIC2 is a phase II/III, multi-centre, prospective, open-label, two-arm randomised superiority clinical trial of azithromycin versus standard care for adults presenting to hospital with COVID-19 symptoms who are not admitted at initial presentation. We will enrol adults, ≥ 18 years of age assessed in acute hospitals in the UK with clinical diagnosis of COVID-19 infection where management on an ambulatory care pathway is deemed appropriate. Participants will be randomised in a 1:1 ratio to usual care or to azithromycin 500 mg orally daily for 14 days with telephone follow-up at days 14 and 28. The primary objective is to compare the proportion with either death or respiratory failure requiring invasive or non-invasive mechanical ventilation over 28 days from randomisation. Secondary objectives include mortality/respiratory failure in those with a PCR-confirmed diagnosis; all-cause mortality; progression to pneumonia; progression to severe pneumonia; peak severity of illness and mechanistic analysis of blood and nasal biomarkers. Discussion This trial will determine the clinical utility of azithromycin in patients with moderately severe, clinically diagnosed COVID-19 and could be rapidly applicable worldwide. Trial registration ClinicalTrials.gov NCT04381962 . Registered on 11 May 2020. EudraCT identifier 2020-001740-26 . Opened for accrual on 29 May 2020.
【저자키워드】 SAR-CoV-2, Azithromycin, Macrolide, Respiratory failure, Mortality, Trial, 【초록키워드】 COVID-19, Coronavirus disease 2019, clinical trial, therapy, Biomarkers, Cytokines, Interleukins, Azithromycin, Macrolide, Respiratory failure, Open-label, randomised, Anti-inflammatory, mechanical ventilation, SARS-CoV, GM-CSF, severity, hospital, risk, nasal, cytokine, Symptom, progression, MERS-CoV, Symptoms, Coronavirus infections, Adults, COVID-19 infection, management, Patient, death, pathway, Bacterial infection, age, pro-inflammatory cytokines, Follow-up, severe pneumonia, Other, disease, Clinical diagnosis, COVID-19 symptoms, Care, moderate, Blood, Ambulatory care, antibiotic, pandemic coronavirus, Analysis, antiviral property, severe disease, Safe, early disease, non-invasive mechanical ventilation, moderate to severe, severity of illness, Therapeutic benefit, Non-invasive, Trial registration, PCR-confirmed, PCR-confirmed diagnosis, standard care, randomisation, usual care, suppression, all-cause mortality, G-CSF, antiviral properties, clinical utility, multi, secondary bacterial infection, Secondary objectives, severe SARS, participant, EudraCT, treat, pro-inflammatory cytokine, anti-inflammatory properties, anti-bacterial, Two-arm, invasive, initial, Course, include, proportion, clinically, diagnosed, determine, reduce, presenting, 1:1, ongoing trial, Opened, Secondary objective, with COVID-19, 【제목키워드】 clinical trial, Azithromycin, Study protocol, randomised, Two-arm,